Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV And Spirogen Enter Into Research Collaboration To Evaluate Potential Of Novel Toxin-Nanobody Drug Conjugates In Cancer- Hugin
Hugin reported that Ablynx NV and Spirogen Ltd. have announced a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies(R) generated using the Company's proprietary technology platform. Under the terms of the collaboration, the Company will provide access to novel Nanobodies against a specific, undisclosed cancer target and Spirogen will provide access to its proprietary cytotoxic warheads (PBDs) and conjugation technologies. Both companies will contribute their resources towards the collaboration, which is expected to last for up to a year initially. Following this feasibility phase, the Company will have the option to either in-license Spirogen's technology or, in collaboration with Spirogen, move development forward with a third party. No further terms have been disclosed.
Latest Developments for Ablynx NV
- Ablynx NV to Present Pre-Clinical Proof-of-Concept Data on ALX-0761 at ACR
- Ablynx NV Elects New Chairman Of Board
- Ablynx NV Updates on Phase II Part of Combined Phase I/II Study of Anti-IL-6R Nanobody, ALX-0061 Results
- Ablynx NV Updates on Results of Phase I/II Study with Anti-Il-6R Nanobody, ALX-0061, in Rheumatoid Arthritis Patients
Latest Key Developments in Biotechnology
- Share this
- Digg this